Filing Flows › Ligand Pharmaceuticals (LGND) › Capital expenditures
Ligand Pharmaceuticals (LGND) capital expenditures by quarter
Ligand Pharmaceuticals' capital expenditures were $26K in Q2 2026 (second quarter 2026), -89% from Q1 2026. Over the last 5 quarters it ranged from $9K (Q4 2025) to $228K (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $26K | -89% | -88% |
| Q1 2026 | $228K | 25× | — |
| Q4 2025 | $9K | -40% | — |
| Q3 2025 | $15K | -93% | — |
| Q2 2025 | $214K | — | — |
Q2 2026 at a glance
Ligand Pharmaceuticals, Q2 2026: revenue $63.7M (+34% year over year), operating margin 13.5%, net earnings $48.5M, operating cash flow $24.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ligand Pharmaceuticals' capital expenditures?
Ligand Pharmaceuticals' capital expenditures were $26K in Q2 2026 (second quarter 2026), -89% from Q1 2026.
How has Ligand Pharmaceuticals' capital expenditures changed?
Over the last 5 quarters it ranged from $9K (Q4 2025) to $228K (Q1 2026).
Q2 2026 results → · How Ligand Pharmaceuticals makes money →